$25.70
-1.94 (-7.02%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CUE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaNCT03978689Dose Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CUE-101, KEYTRUDA®, Pembrolizumab | Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma | 80 | 2026-01-04actual | 2026-01-22 |
| A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersNCT05360680Dose Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CUE-102 | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 42 | 2025-03-12actual | 2026-01-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19